<DOC>
	<DOCNO>NCT00181766</DOCNO>
	<brief_summary>This open-label study daily dose 144 mg/day Strattera ( atomoxetine ) treatment adult attention deficit hyperactivity disorder otherwise specify . The researcher hypothesize ADHD symptomatology adult ADHD NOS responsive Strattera treatment Strattera treatment ( dose 120 mg/day 1.5 mg/kg/day , whichever less ) adult ADHD NOS safe well tolerate .</brief_summary>
	<brief_title>Strattera Treatment Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified ( ADHD NOS )</brief_title>
	<detailed_description>Strattera ( atomoxetine ) non-stimulant specific norepinephrine reuptake inhibitor recently approve Food Drug Administration treatment child , adolescent adult patient ADHD . It possible Strattera could viable alternative treatment ADHD individual . The purpose study ass effectiveness , safety tolerability Strattera adult ADHD NOS . If initial study show promise , follow-up randomized clinical trial . The study include : 1. use six-week design document response rate , 2. weekly assessment document impact Strattera NOS functional capacity , 3. careful assessment safety tolerability . Primary outcome measure symptom reduction .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1 . Male female outpatient older 18 young 55 year age . 2 . Subjects diagnosis attention deficit hyperactivity disorder otherwise specify ( ADHD NOS ) , Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) , manifest clinical evaluation confirm structured interview . This operationalized either : 1. currently least 6/9 current item either inattention hyperactivity/impulsivity &lt; 5 item either list childhood ; 2. 5 9 current DSMIV item inattention and/or hyperactivity/impulsivity , 6 current symptom either category . This second category include independent presence absence ADHD symptom childhood . 3 . Subjects current Clinical Global Impression ADHD score 4 high . 4 . Subjects past history depression anxiety disorder ( include obsessive compulsive disorder [ OCD ] ) without current disorder &gt; 3 month ascertain structured diagnostic interview clinical exam allow participate . 5 . Subjects treat anxiety disorder depression stable medication regimen least three month , disorder specific CGIseverity score â‰¤ 3 ( mildly ill ) score Hamiltondepression Hamiltonanxiety rating scale 15 ( mild range ) include study . 6 . Subjects past history substance use disorder asymptomatic least 6 month negative drug screen allow participate . 7 . Subjects receive nonmonoamine oxidase inhibitor ( MAOI ) antidepressant ( e.g. , selective serotonin reuptake inhibitor [ SSRIs ] , bupropion , venlafaxine ) , benzodiazepines stable regimen &gt; 3 month condition list . 8 . Subjects mild case asthma allergy allow participate . 9 . Subjects acid reflux syndrome allow participate . 10 . Subjects hypercholesterolemia stable dose cholesterollowering medication allow participate . 1 . Any clinically unstable psychiatric condition include follow : acute psychosis , acute panic , acute OCD , acute mania , acute suicidality , lifetime history bipolar disorder , acute substance use disorder ( alcohol drug ) , sociopathy , criminality . 2 . Any metabolic , neurological , hepatic , renal , cardiovascular , hematological , ophthalmic , endocrine disease . 3 . Clinically significant abnormal baseline laboratory value include follow : 1 . Values large 20 % upper range laboratory standard basic metabolic screen . 2 . Exclusionary blood pressure parameter include value 140 ( systolic ) 90 ( diastolic ) . 3 . Exclusionary electrocardiogram ( ECG ) parameter include QTC &gt; 460 msec , QRS &gt; 120 msec , PR &gt; 200 msec . Subjects ECG evidence ischemia arrhythmia review independent cardiologist . 4 . Mental retardation ( intelligence quotient [ I.Q . ] &lt; 75 ) . 5 . Organic brain disorder . 6 . Pregnant nursing female . 7 . Subjects current adequate treatment ADHD history previous adequate trial Strattera . 8 . Subjects fail respond adequate trial , tolerability problem Strattera . 9 . Only Englishspeaking subject allow study follow reason : 1. assessment instrument available adequately standardized language ; 2. researcher ' clinical trial facility locate Cambridge Massachusetts General Hospital ( MGH ) main campus without availability translator ; 3. psychiatric questionnaire evaluation tax add complexity translator potential make patient experience even exhaust . 10 . Prior hypersensitivity Strattera . 11 . MAOI antidepressant use currently within two week start study . 12 . Urinary retention bladder dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>ADHD NOS</keyword>
	<keyword>Adults</keyword>
	<keyword>Strattera ( atomoxetine )</keyword>
	<keyword>Open-Label</keyword>
</DOC>